1 Type of group
Sponsors
CELLTRION, INC.,, NOVARTIS BIOSCIENSES PERU S.A.,
Unknown Phase
STUDY OF SAFETY OF QAW039 IN PATIENTS WITH ASTHMA INADEQUATELY CONTROLLED ON STANDARD-OF-CARE ASTHMA TREATMENT.
Active, not recruitingPER-023-18
Start: 2018-12-10Target: 100Updated: 2023-09-04
A RANDOMIZED, ACTIVE-CONTROLLED, DOUBLE-BLIND, PHASE 3 STUDY TO COMPARE EFFICACY AND SAFETY OF CT-P17 WITH HUMIRA WHEN CO-ADMINISTERED WITH METHOTREXATE IN PATIENTS WITH MODERATE TO SEVERE ACTIVE RHEUMATOID ARTHRITIS
RecruitingPER-040-18
Start: 2019-03-05Target: 100Updated: 2023-09-04
A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF THE SUBCUTANEOUS INJECTION OF CT-P13 (CT-P13 SC) AS MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE
RecruitingPER-022-19
Start: 2019-12-01Target: 40Updated: 2023-11-13
A PHASE 2/3, RANDOMIZED, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CT-P59 IN COMBINATION WITH STANDARD OF CARE IN OUTPATIENTS WITH SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS (SARS-COV-2) INFECTION
RecruitingPER-105-20
Start: 2021-01-22Target: 120Updated: 2023-09-04